Evidence map›Paper›PMID 36241233›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2022

[Bioactive compounds of Jingfang Granules against SARS-CoV-2 virus proteases 3CL

Z P Shang, Y Yi, R Yu, J J Fan, Y X Huang, X Qiao, M Ye

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Z P ShangState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Y YiState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
R YuState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
J J FanState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Y X HuangState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
X QiaoState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
M YeState Key Laboratory of Natural and Biomimetic Drugs, Peking University-Yunnan Baiyao International Medical Research Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveJingfang Granules have been recommended for the prevention and treatment of corona virus disease 2019 (COVID-19). Through chemical analysis and bioactivity evaluation, this study aims to elucidate the potential effective components of Jingfang Granules.

methodsThe inhibitory acti-vities of Jingfang Granules extract against 3-chymotrypsin-like protease (3CL

resultsJingfang Granules exhibited 3CL

conclusionPrim-

Indexed as

Antitussive AgentsCOVID-19Amino AcidsAmmoniaChymasesCoronavirus 3C ProteasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCysteine EndopeptidasesHumansMolecular Docking SimulationPapainPeptide HydrolasesSARS-CoV-2Spike Glycoprotein, CoronavirusTandem Mass SpectrometryAmino AcidsAmmoniaAntitussive AgentsChymasesCoronavirus 3C ProteasesCyclooxygenase 2Cyclooxygenase 2 InhibitorsCysteine EndopeptidasesPapainPeptide HydrolasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-23-chymotrypsin-like proteaseEffective componentsJingfang GranulesPapain like proteaseSevere acute respiratory syndrome coronavirus 2

Identifiers

PMID36241233
PMCPMC9568378
OpenAlexW4306316602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.